Clinical Edge Journal Scan

Affected body surface area predicts risk of PsA in patients with psoriasis


 

Key clinical point: Patients with psoriasis with higher vs. lower affected body surface area (BSA) were at an increased risk of developing psoriatic arthritis (PsA).

Major finding: During a mean follow-up of 4.2 years, the incidence of PsA was 5.4 cases per 1,000 person years. Compared with BSA < 3%, BSA > 10% (hazard ratio [HR] 2.01; 95% CI 1.29-3.13) and BSA = 3%-10% (HR 1.44; 95% CI 1.02-2.03) were associated with incident PsA.

Study details: Findings are from a prospective, population-based cohort study including 9,056 patients with at least 1 code for psoriasis (mild to severe) and 90,547 matched general population controls.

Disclosures: This study was funded by the National Institute of Arthritis and Musculoskeletal and Skin Diseases and the National Heart, Lung, and Blood Institute of the National Institutes of Health. Some authors declared serving as consultant or co-patent holder or receiving grants, honoraria, or payments for medical education from several sources.

Source: Ogdie A et al. Rheumatology. 2021 Sep 11. doi: 10.1093/rheumatology/keab622 .

Recommended Reading

Methotrexate or retinoids: Which one poses lower cardiovascular risks in psoriasis?
MDedge Dermatology
Calcipotriol-betamethasone more effective than calcipotriol alone in treating plaque psoriasis
MDedge Dermatology
Impact of psoriasis on clinical outcomes in patients with pulmonary embolism
MDedge Dermatology
Clobetasol propionate 0.025% is a safe treatment option for moderate-to-severe psoriasis
MDedge Dermatology
Abdominal subcutaneous adipose tissue elicits sex-specific effects on coronary atherosclerosis in psoriasis
MDedge Dermatology
Secukinumab therapy against plaque psoriasis yields high patient satisfaction
MDedge Dermatology
Psoriasis exhibits a strong causal relationship with psychiatric diseases
MDedge Dermatology
Proton pump inhibitors likely promote psoriasis development
MDedge Dermatology
European agency recommends two new adalimumab biosimilars
MDedge Dermatology
Risk of developing PsA significantly lower in psoriasis patients treated with biologics
MDedge Dermatology